Propentofylline (PPT) is a drug used in the treatment of both vascular dementia and Alzheimer type dementia. Hydroxy-metabolites of propentofylline (OHPPT) also demonstrate the same biological activity as the parent compound. As steroisomers of HOPPT are not commercially available, we had to produce them for pharmacological and pharmacokinetic studies. The aim of this study was to find the strains of Saccharomyces cerevisiae yielding enantiomerically pure (R)- or (S)-l-(5-hydroxyhexyl)-3-methyl-7-propylxanthin (OHPPT) from PPT. In this paper, we present the results of stereoselective reduction of PPT into OHPPT when catalysed by whole cells of baker’s and a few strains of wine yeast in water and organic solvents.
Operational Program Digital Poland, 2014-2020, Measure 2.3: Digital accessibility and usefulness of public sector information; funds from the European Regional Development Fund and national co-financing from the state budget.
Feb 18, 2020
Dec 6, 2019
|Enantioselective bioreduction of propentofylline using yeast in water and organic solvents||Feb 18, 2020|
Latacz, Gniewomir Pękala, Elżbieta Kieć-Kononowicz, Katarzyna
Ziółkowski, Piotr Babula- Skowrońska, Danuta Kaczmarek, Małgorzata Cieśla, Agata Sadowski, Jan
Godawska, Anna Pękala, Elżbieta Kieć-Kononowicz, Katarzyna
Nowak, Jacek K.
Institute of Bioorganic Chemistry PAS Committee on Biotechnology PAS